期刊文献+

阿托伐他汀钙对映异构体(S,S)的全合成

Total Synthesis of (3S,5S)-epimers of Atorvastatin Calcium
下载PDF
导出
摘要 合成阿托伐他汀钙对映异构体。方法:以(R)-4-氯-3-羟基丁酸乙酯为起始原料经氰基化、Claisen缩合、羰基还原、O-烃化、氰基还原、与M-4发生Paal-Knorr反应、脱保护、酯水解、成盐等共9步反应合成了阿托伐他汀钙对映异构体(1)。其结构经1H-NMR、ESI-MS、HPLC确证。结论:合成得到了目标化合物,可为阿托伐他汀钙的杂质研究提供可靠参数。 Objective: To synthesis (3S,5S)-epimers of Atorvastatin Calcium. Methods: the (R)-ethyl-4-chloro-3-hydroxybutanoate was used a.s raw material and the (3S,5S)-epimers of Atorvastatin Calcium was obtained by cyanidation, condensation of carbonyl group, O-alkylation,condensation of cyanogroup, Paal-Knorr reaction with M-4, deprotection, hydrolysis of ester, salinization. The structures were confirmed by 1^H-NMR, ESI-MS, HPLC. Conclusion: The target compound was synthesized by this method, which provides an important reference for the research on impurities of atorvastatin.
出处 《广东化工》 CAS 2012年第15期116-117,共2页 Guangdong Chemical Industry
关键词 阿托伐他汀钙对映异构体(S S) 合成 杂质 (3S,5S)-epimersofatorvastatincalcium: synthesis impurities
  • 相关文献

参考文献4

二级参考文献33

  • 1徐颂.阿托伐他汀钙合成路线[J].中国新药杂志,2006,15(22):1913-1917. 被引量:11
  • 2[1]Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia[J]. Drugs 1996; 51: 433-59.
  • 3[2]Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis 1996; 119: 203-13.
  • 4[3]Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase[J]. Am J Cardiol 1994; 73 Suppl D: 3D-11D.
  • 5[4]Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[J]. JAMA 1996; 275: 128-33.
  • 6[5]Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease[J]. Drugs 1997; 53: 299-336.
  • 7[6]Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation[J]. Atherosclerosis 1994; 111: 127-42.
  • 8[7]Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J]. Drugs 1997; 53: 828-47.
  • 9[8]Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study[J]. Clin Ther 1996; 18: 853-63.
  • 10[9]Naoumova RP, Marais D, Firth JC, Neuwirth CKY, Taylor GW, Thompson GR. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants[J]. Circulation 1996; 94(8 Suppl): 583.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部